Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib
Sign Up to like & getrecommendations! Published in 2017 at "Hepatology"
DOI: 10.1002/hep.28720
Abstract: Palbociclib is an oral, small-molecule, specific, and reversible inhibitor of cyclin-dependent kinases 4 and 6, recently approved for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative, metastatic breast cancer. Registration trials witnessed… read more here.
Keywords: treatment palbociclib; metastatic breast; treatment; breast cancer ... See more keywords